Shopping Cart
Remove All
Your shopping cart is currently empty
Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Backorder | Backorder | |
| 5 mg | Inquiry | Backorder | Backorder |
| Description | Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer. |
| Synonyms | SHR-A1811 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 2924909-11-3 |
| Storage | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.